Patients

bioTheranostics, part of the worldwide bioMérieux group, discovers, develops, and commercializes molecular-based diagnostic, prognostic, and predictive tests that support physicians in the treatment of patients with cancer.

Cancer identification and risk assessment

CancerTYPE ID is a molecular test that uses the differential expression of 92 genes to aid in the determination of tumor site of origin.

Breast Cancer Index^SM predicts breast cancer recurrence risk based on proprietary molecular biomarkers.